MD, PhD, Lead Thoracic Oncol. Unit @hospitalclinic, MedOnc, Prof. @unibarcelona, Researcher Transl Genom 🧬 Targeted Therapies @IDIBAPS, @EORTC @GECP_org, #LCSM
Joined March 2017
- Tweets 4,295
- Following 609
- Followers 3,566
- Likes 9,918
Photos and videos
Pinned Tweet
Jun 2
Historic day for #SCLC European Commission has just approved IMDYLLTRA® (tarlatamab), the first and only T-cell engager authorized in Europe for patients with relapsed ES-SCLC. A major step forward for patients!. #LungCancer #ESMO #ASCO26 prnewswire.com/news-releases…
7
30
2,015
Noemi Reguart retweeted
In this episode of the @IASLC podcast, Lung Cancer Considered, Dr. @NarjustFlorezMD & I discuss #ASCO26 immunotherapy highlights with Dr. Julie Brahmer & Dr. @peters_solange, focusing on bispecifics ivonescimab (HARMONi-6) and pumitamig, ADCs, and KRAS.
iaslc.org/iaslc-news/lung-ca…
5
14
42
3,154
🎧 In Part 2 of the #ASCO26 Highlights series, @NarjustFlorezMD and @StephenVLiu are joined by Dr. Julie R. Brahmer and @peters_solange to discuss key immunotherapy advances presented at the 2026 @ASCO Annual Meeting.
The episode covers emerging data on PD-1/VEGF and PD-L1/VEGF bispecific antibodies, ADC-immunotherapy combinations, and promising new strategies for #KRAS-mutant lung cancers.
Listen now : bit.ly/4uZjt6o
#LungCancer #LungCancerConsidered
9
17
1,515
Noemi Reguart retweeted
Details on safety of consolidation osimertinib after chemoradiation for EGFR mutant NSCLC from the phase III LAURA trial. Radiation pneumonitis seen in 48% with osi and 38% with placebo, mostly low grade, 87% continued osi, 93% without recurrence.
lungcancerjournal.info/artic…
2
17
45
4,054
Noemi Reguart retweeted
A pleasure to present for @PeerView , with my colleague @nicogirardcurie , the aspects of identifying, managing and monitoring the special adverse effects of treatment with DLL3-targeting T-cell engagers:
▶️ CRS
▶️ ICANS
▶️ ILD
Link to the webcast:📌 peervoice.com/KDZ
1
1
14
1,020
Noemi Reguart retweeted
🔥Phase 1: ABBV-706 (SEZ6-targeting ADC) in R/R SCLC & solid tumors
🆙 @NatureMedicine
☑R/R SCLC; ORR 52%; mOS 12.4 mo at RP2D
🎯RP2D confirmed at 1.8 mg/kg Q3W balancing efficacy & safety
🎙 @LaurenByersMD
#LCSM @OncoAlert @Larvol
nature.com/articles/s41591-0…
🔁REVIEW #ASCO26 #LCSM Oral
🔥ABBV-706 (SEZ6-ADC) ± Budigalimab in relapsed/refractory SCLC
✅Mono 1.8mg/kg 2L: mOS 14.3m, 15m OS 50%
✅Overall: mOS 11.3m, 15-m OS 40%
🎙️ @LaurenByersMD
🔢8008
☑️NCT05599984
🔗 asco.org/abstracts-presentat…
@OncoAlert @Larvol @ASCO @IASLC
1
8
19
3,265
Noemi Reguart retweeted
🔝Expanding indications of SBRT as a RadicalTreatment 🎯Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study - The Lancet Oncology thelancet.com/journals/lanon…
1
2
225
Noemi Reguart retweeted
🔥🔥 off the press and including latest #ASCO26 data: @ASCO Updated #LivingGuidelines for #LungCancer with driver alterations adds:
1️⃣ EGFR lung cancer 1L - combination tx preferred, osimertinib as alternative
2️⃣EGFR atypical ( G719X, L861Q, S7681) amivantamab lazertinib fist line added based on #CHRYSALLIS2 @EGFRResisters #lcsm
Our new living guideline Therapy for Stage IV NSCLC With Driver Alterations emphasizes broad NGS & IHC (PD-L1, HER2, MET) prior to frontline therapy. Comprehensive profiling is linked to ⬆️ OS & cost-effectiveness in Stage IV NSCLC: bit.ly/4wHjjSf
#LungCancer #NSCLC
1
13
31
3,674
Noemi Reguart retweeted
Important data.
‼️ Landmark #lungcancer research published today in Cell
Scientists at the Francis Crick Institute and UCL have discovered a 14-protein blood signature that predicts lung cancer more than 5 years before diagnosis, works in never-smokers, and could identify who benefits from prevention treatment.
People with high levels of these proteins were the ones who actually benefited from a drug to damp that inflammation down, cutting their lung cancer risk nearly in half.
This could finally give us something lung cancer has never had: a way to prevent it in the people most at risk.
doi.org/10.1016/j.cell.2026.…
#LCSM
11
27
3,942
Noemi Reguart retweeted
🔥🚨 2/2
🤝Grateful to co-authors, including amazing colleagues: Drs @NReguart, Dyer & Hegi-Johnson.
🙏Thankful to Reviewers & Editorial Team.
👏Proud of 1st author @yajur_arya, 1st year Hem/Onc #Fellow & future star, for co-leading the efforts.
#KnowledgeConquersCancer
1
9
684
Noemi Reguart retweeted
🔥🚨1/2 @OncoAlert Hot off the press.
⭐️My co-authors & I are excited & proud to share this, JUST PUBLISHED, #Manuscript in the 2026 #ASCOEdBook in conjunction with #EducationSession Presentation at #ASCO26 @ASCO👇🏻
❇️“#Updates in #SmallCell #LungCancer-NO LONGER TOO SMAL to Ignore. A #Review of Recent #Therapeutic #Advances.”
👇🏻
ascopubs.org/doi/10.1200/EDB…
5
30
83
5,157
Noemi Reguart retweeted
Jun 3
Deulorlatinib demonstrated encouraging anti-tumor activity in patients with advanced ALK-positive NSCLC after failure of second-generation ALK inhibitors, including those with the G1202R mutation. 📑Read more here: bit.ly/4x1sqNH
2
6
398
Noemi Reguart retweeted
⭐️INCREDIBLE #ASCO26 is over but @ASCO’s GREAT mission in helping #Patients #Conquer #Cancer CONTINUES year-over-year.
❇️From one great @ASCOPres theme to another:
✅“The #Science & Practice of #Translation: Improving #Cancer Outcomes #Worldwide.”
⬇️
✅“Intentional #Teams, Exceptional #Care.” x.com/ASCO/status/2061870891…
1
6
40
1,223
Noemi Reguart retweeted
📋 Real-world data published in Lung Cancer @ElsevierConnect on SMALL CELL #lungcancer, thanks to the GECP Thoracic Tumors Registry
🙍♀️🙍♂️ 1,284 patients analyzed after first-line treatment
➡️ The analysis confirms that disease extent, performance status and sensitivity to chemotherapy are key factors for survival
➕ More info: sciencedirect.com/science/ar…
@MARIANOPROVENCI @AVanessaOspinaS @VirginiaCalvo6 @delvysra @BoschBarrera
1
4
11
323
Noemi Reguart retweeted
Dr. Tina Cascone outlines rationale & science behind neoadjuvant and perioperative immunotherapy for early stage NSCLC at #ASCO26. How do we isolate the value of the adjuvant component after pCR or non-pCR? How do we best escalate non-pCR? ADC? Vaccine? Insightful discussion.
1
21
51
3,229
Noemi Reguart retweeted
Jun 3
ESMO is pleased to share the results of the ESMO Presidential Elections. #ESMOElections
Florian Lordick (Germany) will serve as ESMO President 2029–2030 and join the ESMO Executive Board as President‑Elect on 1 January 2027.
🔗 ow.ly/4bJi50Z70I0
4
17
1,868
Noemi Reguart retweeted
Jun 1
Excellent session on several important updates and expert discussions on SCLC at #ASCO2026! Congrats to chairs and presenters @LauraAlderMD @FordePatrick . @LaurenByersMD @drshieldsmd
5
9
614
Jun 1
ABBV-706 (turmetabart adizutecan) a SEZ6-ADC TOP1 inh as monotherapy and in combination with budigalimab in pts R/R-SCLC #ASCO26 @LaurenByersMD. Safety mostly haematologic and GI. Another ADC with promising ORR and preliminary PFS. Now available at nature.com/articles/s41591-0…
9
23
1,318
Noemi Reguart retweeted
Dr. Yun Fan presents data #ASCO26 on ivonescimab liposomal irinotecan in previously treated SCLC. RR 62% (similar in platinum sensitive and resistant) with DOR 7.3m. Safety: diarrhea in 48% (5% G3 ), most common TRAE was anemia.
1
11
24
2,894
Noemi Reguart retweeted
🆙 #ASCO26 #LCSM Oral
🔥Smoking Duration vs Pack-Years for Screening (vs 2021 USPSTF)
✅Missed dx📉 7.5% vs 17.1%
✅Eligibility📈: 28.8%
✅Better equity: Black 83.7% vs 54.0%; Female 83.7% vs 55.1%
🎙️ @BrendanHeiden
🔢8004
🔗 asco.org/abstracts-presentat…
@OncoAlert @Larvol @ASCO @IASLC
8
13
1,492